Markets
Platforms
Accounts
Investors
Partner Programs
Institutions
Contests
Others
loyalty
Partner Loyalty
Trading Tools
Resources
Table of Contents
The biotech industry expands rapidly because of recent medical breakthroughs and therapeutic advancements. Investors can expect substantial profit opportunities because of this industry growth.
The upcoming year 2026 presents an excellent opportunity to invest before market prices increase.
Our research has identified 21 leading biotech stocks in February 2026 that demonstrate promising growth potential and success indicators. Healthcare's future development requires your investment participation through these essential investment opportunities that will help your money grow.
Biotech stocks are entering a major growth phase in 2026, fueled by breakthroughs in gene editing, mRNA technology, and personalized medicine.
The current market presents attractive entry points, with many leading biotech firms trading at discounted valuations despite strong late-stage pipelines.
A risk-managed biotech portfolio should blend large-cap stability, mid-cap growth, and select early-stage innovation for optimal returns.
Here is a list of 21 top biotech stocks to consider for your investment portfolio in February 2026.
S.No
Company (Ticker)
Approx. Price
Country
Sector
1
Vertex Pharmaceuticals (VRTX)
499.63 USD
USA
Healthcare / Biotech
2
Regeneron Pharmaceuticals (REGN)
801.17 USD
3
Gilead Sciences (GILD)
155.70 USD
4
Biogen (BIIB)
197.49 USD
5
Alnylam Pharmaceuticals (ALNY)
316.46 USD
6
Argenx (ARGX)
836.80 USD
Netherlands
7
BioMarin Pharmaceutical (BMRN)
60.03 USD
8
Incyte Corporation (INCY)
101.67 USD
9
CRISPR Therapeutics (CRSP)
53.18 USD
10
Beam Therapeutics (BEAM)
28.33 USD
11
Intellia Therapeutics (NTLA)
12.06 USD
12
Moderna (MRNA)
42.07 USD
13
Genmab A/S (GMAB)
31.80 USD (ADR)
Denmark
14
CSL Limited (CSL)
109.20 USD
Australia
15
Novo Nordisk (NVO)
46.85 USD
16
Lonza Group (LZAGY)
68.34 USD
Switzerland
Healthcare / Life Sciences
17
Karuna Therapeutics (KRTX)
329.83 USD
18
Madrigal Pharmaceuticals (MDGL)
468.96 USD
19
Viking Therapeutics (VKTX)
29.95 USD
20
Summit Therapeutics (SMMT)
15.25 USD
21
Structure Therapeutics (GPCR)
71.20 USD
The U.S.-based biopharmaceutical company Vertex maintains its position as the leading cystic fibrosis (CF) treatment provider through its dominant market position which reaches approximately 90% of global sales.
Company Details
Market Cap: $126.68B
Revenue: $12.00B
Net Income: $3.95B
The company Regeneron is a major biopharmaceutical player, known for its biologic therapies in ophthalmology (EYLEA®) and immunology/oncology (e.g., Dupixent® via partner).
Market Cap: $82.20B
Revenue: $14.34B
Net Income: $4.50B
The company Gilead is a global biopharma leader in HIV, liver disease, and oncology therapies, with a broad product base and scale. It continues to evolve strategy toward higher-growth areas while managing legacy assets.
Market Cap: $193.83B
Revenue: $29.44B
Net Income: $8.51B
The company Biogen is focused on neurology, with key assets in multiple sclerosis (MS) and Alzheimer’s disease, and is undergoing portfolio transformation toward rare diseases and immunology.
Market Cap: $28.96B
Revenue: $9.89B
Net Income: $1.29B
The company Alnylam leads the field of RNA interference (RNAi) therapeutics by providing first-in-class treatments for rare genetic diseases. The platform of the company continues to expand the possibilities of gene silencing technologies.
Market Cap: $41.46B
Revenue: $3.71B
Net Income: $313.75M
Argenx develops antibody-based treatments for autoimmune diseases through its proprietary FcRn platform. Its lead product, VYVGART®, continues to expand globally across multiple indications.
Market Cap: $51.05B
Revenue: $3.68B
Net Income: $1.53B
BioMarin focuses on rare genetic disorders and enzyme replacement therapies. Its new gene therapy Roctavian® for hemophilia A marks a major commercial milestone.
Market Cap: $11.57B
Revenue: $3.09B
Net Income: $520.42M
Incyte is an oncology and immunology company best known for Jakafi® and its expanding dermatology portfolio led by Opzelura®.
Market Cap: $20.18B
Revenue: $5.14B
CRISPR Therapeutics pioneers gene-editing technologies and co-developed Casgevy®, the first FDA-approved CRISPR therapy for sickle-cell disease and β-thalassemia.
Market Cap: $5.11B
Revenue: $3.51M
Net Income: $-581.60M
Beam Therapeutics develops next-generation gene-editing therapies using precision base editing technology designed to correct genetic mutations without cutting DNA. The company’s collaborations with Pfizer and Verve Therapeutics enhance its clinical reach.
Market Cap: $2.77B
Revenue: $55.70M
Net Income: $-414.64M
Intellia Therapeutics focuses on in-vivo and ex-vivo CRISPR-based gene editing. It is among the first to demonstrate systemic in-vivo editing in humans with encouraging early clinical data in transthyretin amyloidosis.
Market Cap: $1.39B
Revenue: $57.53M
Net Income: $-445.81M
Moderna is a global biotechnology leader pioneering mRNA-based vaccines and therapeutics. Following its COVID-19 success, the company is expanding into oncology, RSV, and rare-disease applications.
Market Cap: $16.78B
Revenue: $1.94B
Net Income: $-2.82B
Genmab operates as a Danish biotech organization which focuses on developing antibody-based cancer therapies through innovative approaches.
Market Cap: $115.87B
Revenue: $24.48B
Net Income: $10.08B
CSL operates as a major Australian biopharmaceutical organization which focuses on plasma therapies alongside vaccines and rare disease treatments.
Market Cap: $72.31B
Revenue: $23.10B
Net Income: $2.09B
The company Novo Nordisk is a global leader in diabetes and obesity care, driven by its semaglutide-based therapies (like Wegovy® and Ozempic®). It continues to expand manufacturing capacity and global reach.
Market Cap: $219.20B
Revenue: $48.59B
Net Income: $16.10B
Lonza Group operates as a major contract development and manufacturing organization (CDMO) in biologics, cell & gene therapies, and small molecules, servicing global pharma & biotech clients.
Market Cap: $45.48B
Revenue: $8.24B
Net Income: $1.20B
Karuna is a clinical-stage biopharmaceutical company developing therapies for psychiatric and neurologic disorders (notably its lead candidate KarXT).
Market Cap: $2.82B
Revenue: $7.48B
Net Income: $295.00M
Madrigal develops therapies for liver-metabolic diseases (notably NASH/MAFLD) and has recently launched its first commercial product following FDA approval, positioning it for rapid growth.
Market Cap: $10.55B
Revenue: $740.64M
Net Income: $-289.13M
Viking is a clinical-stage biotech developing metabolic and endocrine drugs, including oral candidates in obesity and liver disease.
Market Cap: $3.43B
Revenue: n/a
Net Income: $-359.64M
Summit Therapeutics operates as a U.S.based biopharmaceutical company which specializes in precision oncology through its lead asset Ivonescimab that targets TP53-mutant and other challenging-to-treat cancers.
Market Cap: $11.64B
Net Income: $-921.62M
Structure Therapeutics is a clinical-stage biotech developing novel oral small-molecule therapies targeting G-protein coupled receptors (GPCRs) for metabolic and pulmonary diseases
Market Cap: $4.96B
Net Income: $-210.69M
These biotech stocks were selected based on their exposure to breakthrough areas such as gene editing, personalized medicine, and mRNA technologies. We focused on companies with strong late-stage clinical pipelines, strategic partnerships, and clear commercialization pathways. Financial strength, cash runway, and innovation depth were key factors in the screening process. The selection aims to capture firms positioned to benefit from new product launches and expanding market adoption through 2026 and beyond.
Clinical trial failures or regulatory rejections can significantly impact company valuations and growth prospects.
High research and development costs with uncertain outcomes can create funding and profitability challenges.
Smaller or early-stage biotech firms tend to have higher volatility and financial risk compared to established biopharma companies.
Overconcentration in a single therapy area or company increases exposure to scientific, regulatory, and market uncertainties.
The 21 biotech stocks for 2026 represent both established leaders and high-growth innovators, which makes them exciting investment opportunities. The high potential rewards come with significant risks, which require investors to diversify their portfolios and conduct continuous research.
These biotech stock investment choices offer healthcare investors a solid foundation to access future healthcare opportunities. If you are looking to expand further, feel free to also explore areas like Pharma stocks and Healthcare stocks to build a well-rounded portfolio.
Ready for the Next Trading Step?
Open an account and get started.
Calculate lot sizes and risk.
Convert currencies in real-time.
Learn key trading terms and concepts.
Leverage your insights and take the next step in your trading journey with an XS trading account.
Publicly traded companies that operate in biotechnology develop drugs and therapies and medical technologies through biological processes make up the sector of biotech stocks.
The success of biotech companies depends heavily on the clinical trial outcomes of their limited number of drug candidates. Stock prices experience substantial fluctuations when regulatory delays occur or when trials fail or the market rejects new drugs.
Biotech stocks present high growth potential despite their associated risks. Companies that achieve success in gene editing and personalized medicine and drug development breakthroughs can generate substantial returns.
The price of biotech stocks experiences significant changes based on FDA approval or rejection decisions. Positive results from FDA approvals typically cause stock prices to surge while negative results from FDA rejections lead to significant stock price declines.
Yes. The IBB and XBI ETFs provide diversified exposure to multiple companies which reduces the risk of individual stock picks.
The key factors include clinical trial updates, FDA approval timelines, financial health, competitive positioning, and overall market sentiment in healthcare innovation.
Jennifer Pelegrin
Technical Financial Writer
Jennifer brings over five years of experience in crafting high-quality financial content for digital platforms. As a Technical Financial Writer, her work focuses on explaining complex financial and cybersecurity topics in a clear, structured, and practical manner for a broad audience.
No comments yet. Be the first to comment.
This written/visual material is comprised of personal opinions and ideas and may not reflect those of the Company. The content should not be construed as containing any type of investment advice and/or a solicitation for any transactions. It does not imply an obligation to purchase investment services, nor does it guarantee or predict future performance. XS, its affiliates, agents, directors, officers or employees do not guarantee the accuracy, validity, timeliness or completeness of any information or data made available and assume no liability for any loss arising from any investment based on the same. Our platform may not offer all the products or services mentioned.
On the UK side, the Bank of England continues to hold interest rates around 3.75% and remains cautious in its next policy steps. The UK...
11 Best Trading Books Every Trader Should Read in 2026 If you are interested in trading but don’t know how to start, here is a...
Currently, gold is trading around $5,020/oz, close to an important support zone at $5,000–$5,020/oz. This area has repeatedly acted as support during previous pullbacks and...
Stay in the loop with our latest announcements, product releases, and exclusive insights, delivering straight to your inbox.